Metformin use and cervical cancer risk in female patients with type 2 diabetes

Oncotarget

Volumn 7, Issue 37, 2016, Pages 59548-59555

  Tseng, Chin Hsiao ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Cervical cancer; Diabetes mellitus; Metformin; Taiwan

Indexed keywords

INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NATIONAL HEALTH INSURANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROBABILITY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RISK REDUCTION; TAIWAN; UTERINE CERVIX CANCER; CHEMICALLY INDUCED; INCIDENCE; MIDDLE AGED; OUTCOME ASSESSMENT; PROCEDURES; STATISTICS AND NUMERICAL DATA; UTERINE CERVIX TUMOR;

AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; METFORMIN; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; TAIWAN; UTERINE CERVICAL NEOPLASMS;

EID: 84991358660     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10934     Document Type: Article

References (51)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90
2. Lee KM, Lee M, Lee J, Kim SW, Moon HG, Noh DY, Han W. Enhanced anti-tumor activity and cytotoxic effect on cancer stem cell population of metformin-butyrate compared with metformin HCl in breast cancer. Oncotarget. 2016 May 20. doi: 10.18632/oncotarget.9522. [Epub ahead of print]
3. Liu Z, Qi S, Zhao X, Li M, Ding S, Lu J, Zhang H. Metformin inhibits 17β-estradiol-induced epithelial-tomesenchymal transition via βKlotho-related ERK1/2 signaling and AMPKa signaling in endometrial adenocarcinoma cells. Oncotarget. 2016 Jan 27. doi: 10.18632/oncotarget.7040. [Epub ahead of print]
4. Al-Wahab Z, Mert I, Tebbe C, Chhina J, Hijaz M, Morris RT, Ali-Fehmi R, Giri S, Munkarah AR, Rattan R. Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction. Oncotarget. 2015; 6:10908-23. doi: 10.18632/oncotarget.3434
5. Della Corte CM, Ciaramella V, Di Mauro C, Castellone MD, Papaccio F, Fasano M, Sasso FC, Martinelli E, Troiani T, De Vita F, Orditura M, Bianco R, Ciardiello F, et al. Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells. Oncotarget. 2016; 7:4265-78. doi: 10.18632/oncotarget.6559
6. Park J, Kim WG, Zhao L, Enomoto K, Willingham M, Cheng SY. Metformin blocks progression of obesityactivated thyroid cancer in a mouse model. Oncotarget. 2016 Apr 26. doi: 10.18632/oncotarget.8989. [Epub ahead of print]
7. Tian Y, Tang B, Wang C, Sun D, Zhang R, Luo N, Han Z, Liang R, Gao Z, Wang L. Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. Oncotarget. 2016 Jun 15. doi: 10.18632/oncotarget.10079. [Epub ahead of print]
8. Moon HS, Mantzoros CS. Regulation of cell proliferation and malignant potential by irisin in endometrial, colon, thyroid and esophageal cancer cell lines. Metabolism. 2014; 63:188-93
9. Yue W, Zheng X, Lin Y, Yang CS, Xu Q, Carpizo D, Huang H, DiPaola RS, Tan XL. Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. Oncotarget. 2015; 6:21208-24. doi: 10.18632/oncotarget.4126
10. Yu G, Fang W, Xia T, Chen Y, Gao Y, Jiao X, Huang S, Wang J, Li Z, Xie K. Metformin potentiates rapamycin and cisplatin in gastric cancer in mice. Oncotarget. 2015; 6:12748-62. doi: 10.18632/oncotarget.3327
11. Akhtar N, Syed DN, Khan MI, Adhami VM, Mirza B, Mukhtar H. The pentacyclic triterpenoid, plectranthoic acid, a novel activator of AMPK induces apoptotic death in prostate cancer cells. Oncotarget. 2016; 7:3819-31. doi: 10.18632/oncotarget.6625
12. Liu Q, Yuan W, Tong D, Liu G, Lan W, Zhang D, Xiao H, Zhang Y, Huang Z, Yang J, Zhang J, Jiang J. Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis. Oncotarget. 2016 Apr 5. doi: 10.18632/oncotarget.8595. [Epub ahead of print]
13. Velez J, Pan R, Lee JT, Enciso L, Suarez M, Duque JE, Jaramillo D, Lopez C, Morales L, Bornmann W, Konopleva M, Krystal G, Andreeff M, Samudio I. Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport. Oncotarget. 2016 Jun 6. doi: 10.18632/oncotarget.9843. [Epub ahead of print]
14. Tseng CH. Diabetes, metformin use, and colon cancer: A population-based cohort study in Taiwan. Eur J Endocrinol. 2012; 167:409-16
15. Tseng CH. Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes. Acta Diabetol. 2014; 51:295-303
16. Tseng CH. Metformin may reduce breast cancer risk in Taiwanese women with type 2 diabetes. Breast Cancer Res Treat. 2014; 145:785-90
17. Tseng CH. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus. Eur J Cancer. 2014; 50:2831-7
18. Tseng CH. Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes. PLoS One. 2014; 9:e109852
19. Tseng CH. Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan. Gynecol Oncol. 2015; 138:147-53
20. Tseng CH. Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2015; 31:619-26
21. Tseng CH. Use of metformin and risk of kidney cancer in patients with type 2 diabetes. Eur J Cancer. 2016; 52:19-25
22. Tseng CH. Metformin may reduce oral cancer risk in patients with type 2 diabetes. Oncotarget. 2016; 7:2000-8. doi: 10.18632/oncotarget.6626
23. Xiao X, He Q, Lu C, Werle KD, Zhao RX, Chen J, Davis BC, Cui R, Liang J, Xu ZX. Metformin impairs the growth of liver kinase B1-intact cervical cancer cells. Gynecol Oncol. 2012; 127:249-55
24. Kwan HT, Chan DW, Cai PC, Mak CS, Yung MM, Leung TH, Wong OG, Cheung AN, Ngan HY. AMPK activators suppress cervical cancer cell growth through inhibition of DVL3 mediated Wnt/β-catenin signaling activity. PLoS One. 2013; 8:e53597
25. Yung MM, Chan DW, Liu VW, Yao KM, Ngan HY. Activation of AMPK inhibits cervical cancer cell growth through AKT/FOXO3a/FOXM1 signaling cascade. BMC Cancer. 2013; 13:327
26. Do MT, Kim HG, Khanal T, Choi JH, Kim DH, Jeong TC, Jeong HG. Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERKNrf2 signaling and AMPK-independent pathways. Toxicol Appl Pharmacol. 2013; 271:229-38
27. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003; 158:915-20
28. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008; 167:492-9
29. Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med. 2013; 32:2837-49
30. Parsons LS. Performing a 1:N case-control match on propensity score. http://www.google.com.tw/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CBsQFjAAahUKEwibi7HllcnIAhUDoJQKHVeZA9A&url=2F%2Fwww2.sas.com%2Fproceedings%2Fsugi29%2F165-29.pdf&usg=AFQjCNFOHGWYu8E8Bn4-Bo1TUiJKtT987Q (last accessed October 17, 2015)
31. Fernandes JV, DE Medeiros Fernandes TA, DE Azevedo JC, Cobucci RN, DE Carvalho MG, Andrade VS, DE Araújo JM. Link between chronic inflammation and human papillomavirus-induced carcinogenesis (Review). Oncol Lett. 2015; 9:1015-26
32. Chu NJ, Armstrong TD, Jaffee EM. Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention. Clin Cancer Res. 2015; 21:1549-57
33. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A. 2015; 112:1809-14
34. Corominas-Faja B, Quirantes-Piné R, Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Martin-Castillo B, Micol V, Joven J, Segura-Carretero A, Menendez JA. Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY). 2012; 4:480-98
35. Xun YH, Zhang YJ, Pan QC, Mao RC, Qin YL, Liu HY, Zhang YM, Yu YS, Tang ZH, Lu MJ, Zang GQ, Zhang JM. Metformin inhibits hepatitis B virus protein production and replication in human hepatoma cells. J Viral Hepat. 2014; 21:597-603
36. del Campo JA, García-Valdecasas M, Rojas L, Rojas á, Romero-Gómez M. The hepatitis C virus modulates insulin signaling pathway in vitro promoting insulin resistance. PLoS One. 2012; 7:e47904
37. Li C, Kong D. Cancer risks from diabetes therapies: evaluating the evidence. Pharmacol Ther. 2014; 144:71-81
38. Tseng CH. Use of insulin and mortality from breast cancer among Taiwanese women with diabetes. J Diabetes Res. 2015; 678756
39. Tseng CH. Prolonged use of human insulin increases breast cancer risk in Taiwanese women with type 2 diabetes. BMC Cancer. 2015; 15:846
40. Tseng CH. Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes. Eur J Clin Invest. 2016; 46:70-9
41. Tseng CH. Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes. Oncotarget. 2016 Mar 28. doi: 10.18632/oncotarget.8399. [Epub ahead of print]
42. Tseng CH. A review on thiazolidinediones and bladder cancer in human studies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2014; 32:1-45
43. Tseng CH, Lee KY, Tseng FH. An updated review on cancer risk associated with incretin mimetics and enhancers. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2015; 33:67-124
44. Tseng CH. Sitagliptin and heart failure hospitalization in patients with type 2 diabetes. Oncotarget. 2016 Jul 9. doi: 10.18632/oncotarget.10507. [Epub ahead of print]
45. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371:569-78
46. Tseng CH. Obesity paradox: differential effects on cancer and noncancer mortality in patients with type 2 diabetes mellitus. Atherosclerosis. 2013; 226:186-92
47. Stevens RJ, Ali R, Bankhead CR, Bethel MA, Cairns BJ, Camisasca RP, Crowe FL, Farmer AJ, Harrison S, Hirst JA, Home P, Kahn SE, McLellan JH, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative metaanalysis of randomised clinical trials. Diabetologia. 2012; 55:2593-603
48. Tseng CH. Pioglitazone and bladder cancer: a populationbased study of Taiwanese. Diabetes Care. 2012; 35:278-80
49. Tseng CH. Type 2 diabetes mellitus and kidney cancer risk: a retrospective cohort analysis of the National Health Insurance. PLoS One. 2015; 10:e0142480
50. Tseng CH. Sitagliptin increases acute pancreatitis risk within 2 years of its initiation: A retrospective cohort analysis of the National Health Insurance database in Taiwan. Ann Med. 2015; 47:561-9
51. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015; 34:3661-79